References
 
  1. Ball D.W., Baylin S.B., De Butros A.C. Medullary thyroid carcinoma, In : Werner and Ingbar’s The Thyroid, Eighth Edition. Braverman L.E. and Utiger R.E. (Eds). Lippincott-Williams-Wilkins, Philadelphia, 2000, 930- 943.


  2. Donovan D.T., Gagel R.F. Medullary thyroid carcinoma and the Multiple Endocrine Neoplasia Syndromes. In: Thyroid Diseases: endocrinology, surgery, nuclear medicine and radiotherapy, 2nd Edition, Falk. A (Ed) Lippincott-Raven. Philadelphia,1997: 619-644.


  3. Mathew C.G.P., Chin K.S., Easton D.F., Thorpe K., Carter C, Liou G.I., Fong S.L., Bridges C.D.B., Haak H, Nieuwenhuijzen Kruseman A.C., Schifter S., Hansen H.H, Telenius H., Telenius-Berg M., Ponder B.A.J. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987, 328: 527-528.


  4. Simpson NE, Kidd KK, Goodfellow PJ, Mc Dermid H, Myers S, Kidd JR. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987, 328: 528-530.


  5. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2: 851-856.


  6. Hofstra R.M, Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Hoppener J.W.M., Ploos Van Amstel H.K., Romeo G, Lips C.J.M., Buys C.H.C.M. Amutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367: 375-376.


  7. Mulligan L.M., Eng C., Healey C.S., Clayton D., Kwok J.B.J., Gardner E., Ponder M.A., Frilling A., Jackson C.E., Lehnert H., Neumann H.P.H., Thibodeau S.N., Ponder B.A.J. Specific mutations of the RET proto-oncogene are related to disease phenotype in NEM 2a and FMTC. Nature Genetics 1994, 6: 70-74.


  8. Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., Raue F., Ritter M.M, Höppner W. A new hot spot for mutations in the ret protooncogene causing familial medullary carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998, 83: 770-774.


  9. Bollino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., Chabrier G., Houdent C., Murat A., Schlumberger M., Tourniaire J., Lenoir G.M., Romeo G. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995, 10: 2415-2419.


  10. Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10: 509-513.


  11. Eng C., Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R.F., Ploos Van Amstel H.K., Lips C.J.M., Nishisho I., Takai S.I., Marsh D.J., Robinson B.G., Frank-Raue K., Raue F., Xue F., Noll W.W, Romei C., Pacini F., Fink M., Niederle B., Zedenius J., Nordensk L.D. M., Komminoth P., Hendy G.N, Gharib H., Thibodeau S.N., Lacroix A., Frilling A., Ponder B.A.J., Mulligan L.M. The relationship between specific RET proto-oncogene mutation and disease phenotype in multiple endocrine neoplasia type 2: international RET Mutation Consortium Analysis. JAMA 1996, 276: 1575-1579.


  12. Hofstra R.M.V., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U., Colantuoni V., Buys C.H.C.M. A novel point mutation in the intracellular domain of the ret proto-oncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997, 82: 4176-4178.


  13. Pigny P., Bauters C., Wemeau JL., Lecomte Houcke M., Crepin M., Caron P., Giraud S. , Calender A., Buisine MP., Kerckaert JP., Porchet N. Anovel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2000, 84: 1700-1704.


  14. Schuffenecker I., Ginet N., Goldgar D., Eng C., Chambe B., Boneu A., Houdent C., Pallo D, Schlumberger M, Thivolet C., Lenoir G.M. Prevalence and parental origin of de novo RET mutations in MEN 2a and FMTC. Am J Hum Genet 1997, 60: 233-237.


  15. Rossel M., Schuffenecker I., Schlumberger M., Bonnardel C., Modigliani E., Gardet P., Navarro J., Luo Y., Romeo G., Lenoir G., Billaud M. A single point mutation in the RET proto-oncogene is associated with the majority of MEN 2B. Human Genetics 1995, 35: 403-406.


  16. Carlson K.M., Bracamontes J., Jackson C.E., Clark R., Lacroix A., Wells S.A., Goodfellow P.J. Parent of origin effects in multiple endocrine neoplasia type 2b. Am J Hum Genet 1994, 55: 1076-1082.


  17. Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., Zajac J.D., Robinson B.G., Eng C. Germline dinucleotide mutation in codon 883 of the ret proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997, 82: 3902-3904.


  18. Gagel R.F., Levy M.L., Donovan D.T., Alford B.R., Wheeler T., Tschen J.A. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989, 111: 802-806.


  19. Caron P., Attie T., David D., Amiel J., Brousset F., Roger P., Munnich A., Lyonnet S. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. J Clin Endocrinol Metab 1996, 81: 2731-2733.


  20. Santoro M. Carlomagno F., Romano A., Botaro D.P., Dathan.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., Di Fiore P.P.. Activation of RET as a dominant transforming gene by germline mutations of MEN 2a and MEN 2b. Science 1995, 267: 381-383.


  21. Michiels F.M., Chappuis S., Caillou B., Pasini A., Talbot M., Monier R., Lenoir G.M., Feunteun J., Billaud M. Development of medullary thyroid carcinoma in transgenic mice expressing the RET proto-oncogene altered by a multiple endocrine neoplasia type 2A mutation. PNAS 1997, 94: 3330-3335.


  22. Rosai J., Carcangiu M.L, De Lellis R.A. Tumors of the thyroid gland. In : Atlas of tumor pathology. 3rd series. Fascile 5. Washington, DC :Armed Forces Institute of Pathology, 1992.


  23. Hedinger C., Williams E.D, Sobin L.H. Histological typing of thyroid tumours. 2ndEd n°11 of International classification of tumours. Berlin, Germany: Springer-Verlag, 1988.


  24. Pacini F., Fontanelli M., Fugazzola L., Elisei R., Romei C., Di Coscio G., Miccoli P., Pinchera A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994, 78: 826-829.


  25. Ponder B.A.J., Ponder M.A., Coffey R., Pembrey M.E., Gagel R.F., Telenius-Berg M., Semple P., Easton D.F. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988, 2: 397-401.


  26. Gagel R.F., Jackson C.E., Block M.A., Feldman ZT, Reichlin S, Hamilton BP, Tashjian AH. Age related probability of development of hereditary medullary thyroid carcinoma. J Pediatr 1982, 101: 941-946.


  27. Gagel R.F., Tashjian A.H., Cummings T., Papathanasopoulos N., Kaplan M.N, De Lellis R.A., Wolfe H.J., Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18- year experience. N Engl J Med 1988, 318: 478-484.


  28. Lips CJM, Landsvater RM, Hoppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn Van Veen JM, Van Gils APG, De Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos Van Amstel HK, Van Vroo Nhoven TJMV, Vroom TM. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasie type 2a. N Engl J Med 1994, 331: 828-835.


  29. Vasen H.F.A., Van Der Feltz M., Raue F., Kruseman A.N, Koppeschaar H.P.F., Pieters G., Seif F.J., Blum W.F., Lips C.J. The natural course of multiple endocrine neoplasia type IIb. Astudy of 18 cases. Arch Intern Med 1992, 152: 1250-1252.


  30. Crosfeld F.J.M., Lips C.J.M., Ten Kroode H.J.F., Beemer FA., Van Spijker H.G., Brouwers-Smalbraak G.J. Psychosocial consequences of DNA analysis for MEN Type 2. Oncology, 1996, 10: 141-157.


  31. Freyer G., Dazord A., Schlumberger M, Conte-Devolx B., Ligneau B., Trillet-Lenoir V., Lenoir G. Psychosocial impact of genetic testing in familial medullary thyroid carcinoma :a multicentric pilot-evaluation. Ann Oncol 1999, 10: 87-95.


  32. Bell B., Mazzaferri EL. Familiar adenomatous polyposis (Gardner’s Syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci 1993, 38: 185-190.


  33. Harach HH., Williams GT., Williams ED. Familial adenomatous polyposis associated thyroid carcinoma : a distinct type of follicular cell neoplasm. Histopathology 1994, 25: 549-561.


  34. Cetta F., Montalto G., Gori M., Curia MC., Cama A., Olschwang S. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma : results from a european cooperative study. J Clin Endocrinol Metab 2000, 85: 286- 292.


  35. Mallory SB. Cowden Syndrome (Multiple Hamartoma Syndrome). Dermatologic Clinics 1995, 13: 27-31.


  36. Stratakis CA., Courcoutsakis NA., Abati A., Filie A., Doppman JL., Carney JA., Shawker T. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997, 82: 2037-2043.


  37. Burgess JR., Duffield A., Wilkinson SJ., Ware R., Greenaway TM., Percival J., Hoffman L. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab 1997, 82: 345-348.


  38. Grossman RF., Tu SH. , Duh QY., Siperstein AE., Novosolov F., Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995, 130: 892-899.


  39. Hrafnkelsson J., Tulinius H., Jonasson JG., Olafsdottir G., Sigvaldason H. Papillary thyroid carcinoma in Iceland. A study of the occurrence in families and the coexistence of other primary tumours. Acta Oncol 1989, 6: 785-788.


  40. Leprat F., Bonichon F., Guyot M., Trouette H., Trojani M., Vergnot V., Longy M., Belleannée G., de Mascarel A., Roger P. Familial non-medullary thyroid carcinoma :pathology review in 27 affected cases from 13 french families. Clin Endocrinol 1999, 50: 589-594.


  41. Lesueur F., Stark M., Tocco T., Ayadi H., Delisle MJ., Goldgar DE., Schlumberger M., Romeo G., Canzian F. Genetic heterogeneity in familial non-medullary thyroid carcinoma :exclusion of linkage to RET, MNG1 and TCO in 56 families. J Clin Endocrinol Metab 1999, 84: 2157-2162.


  42. Lote K., Andersen K., Nordal E., Brennhovd IO. Familial occurrence of papillary thyroid carcinoma. Cancer 1980, 46 :1291-1297.


  43. Nikiforov YE., Fagin JA. Prevalence, significance, and biological behaviour of RET-PTC associated papillary thyroid carcinoma. J Clin Endocrinol Metab 1997, 82: 2016-2017.


  44. Ozaki O., Ito K., Kobayashi SJ., Suzuki A., Manabe Y., Hosoda Y. Familial occurrence of differentiated, non-medullary thyroid carcinoma. World J Surg 1988, 12: 565-571.


  45. Ron E., Kleinerman RA., LiVolsi VA., Fraumeni Jr JF. Familial nonmedullary thyroid cancer. Oncology 1991, 18: 309-311.


  46. Stoffer SS., Van Dyke DL., Vaden Bach J., Szpunar W., Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet 1986, 25: 775-782.


  47. Canzian F., Amati P., Harach HR., Kraimps JL., Lesueur F., Barbier J., Levillain P., Romeo G., Bonneau D. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998, 63: 1743-1748.


  48. Malchoff CD., Sarfarazi M., Tendler B., Forouhar F., Whalen G., Joshi V., Arnold A., Malchoff DM. Papillary thyroid carcinoma associated with papillary renal neoplasia :genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000, 85: 1758-1764.


  49. Goldgar DE., Easton DF., Cannon-Albright LA., Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer inst. 1994, 86: 1600-1608.


  50. Hemminki K., Dong C. Familial relationships in thyroid cancer by histo-pathological type. Int j Cancer 2000, 85: 201-205.


  51. Schneider AB., Shore-Freedman E., Weinstein RA. Radiation-induced thyroid and other neck and head tumors :occurrence of multiple tumors and analysis of risk factors. J Clin Endocrinol Metab 1986, 63 :107-112.


  52. Perkel VS., Gail MH., Lubin J., Pee DY., Weinstein R., Shore-Freedman E., Schneider AB. Radiation-induced thyroid neoplasms :evidence for familial susceptibility factors. J Clin Endocrinol Metab 1988, 66: 1316-1322.


  53. Leprat F., Alapetite C., Rosselli P., Ridet A., Schlumberger M., Sarasin A., Suarez HG., Moustacchi E. Impaired DNA repair as assessed in patients with thyroid tumors after a history of radiation therapy :a preliminary study. Radiat Oncol Biol Physics 1998, 40: 1019-1026.


  54. De Vathaire F., Hardiman C., Shamsaldin A., Campbell S., Grimaud E., Hawkins M., Raquin M., Oberlin O., Diallo I., Zucker M., Panis X., Lagrange LN., Daly-Schveitzer N., Lemerle J., Chavaudra J., Schlumberger M., Bonaiti C. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 1999, 159: 2713-2720.